Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01. Changes in Registrant’s Certifying Accountant.
As previously reported in the Current Report on Form 8-K dated April 24, 2017, the Audit Committee (the “Committee”) of the Board of Directors of Anika Therapeutics, Inc. (the “Company”) dismissed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the three-month period ended March 31, 2017 with the Securities and Exchange Commission (“SEC”). The Committee also approved the appointment of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017, with such appointment of Deloitte to become effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the three-month period ended March 31, 2017. On May 4, 2017, the Company filed its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2017. As a result of filing such Quarterly Report on Form 10-Q, PwC’s appointment as the Company’s independent registered public accounting firm ended, and Deloitte’s appointment as the Company’s independent registered public accounting firm became effective.
The reports of PwC on the Company’s consolidated financial statements for the fiscal years ended December 31, 2016 and 2015 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the fiscal years ended December 31, 2016 and 2015, and in the subsequent interim period through May 4, 2017, there were: (a) no disagreements with PwC on any matters of accounting principles or practices, financial statement disclosure or auditing scope or procedure which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference to the matter in their reports on the consolidated financial statements for such years; and (b) no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).
The Company has provided a copy of the foregoing disclosures to PwC and requested that PwC furnish it with a letter addressed to the SEC stating whether PwC agrees with the above statements. A copy of PwC’s letter, dated May 5, 2017, is filed as Exhibit 16.1 to this Form 8-K.
During the two most recent fiscal years and in the subsequent interim period through May 4, 2017, neither the Company nor anyone on its behalf has consulted with Deloitte with respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue or (ii) any matter that was either the subject of a disagreement or a reportable event, each as described in Regulation S-K Item 304(a)(1)(v).
Section 9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
16.1 Letter from PricewaterhouseCoopers LLP regarding change in certifying accountant dated May 5, 2017.
[Remainder of page left blank intentionally]
About Anika Therapeutics, Inc. (NASDAQ:ANIK)
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL. Anika Therapeutics, Inc. (NASDAQ:ANIK) Recent Trading Information
Anika Therapeutics, Inc. (NASDAQ:ANIK) closed its last trading session up +0.35 at 44.75 with 173,187 shares trading hands.